A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF ATEZOLIZUMAB IN COMBINATION WITH OBINUTUZUMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 25 Apr 2018
At a glance
- Drugs Atezolizumab (Primary) ; Lenalidomide; Obinutuzumab
- Indications Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 28 Mar 2018 Planned End Date changed from 31 Jan 2020 to 20 Mar 2021.
- 28 Mar 2018 Planned primary completion date changed from 31 Jan 2020 to 20 Mar 2021.
- 28 Mar 2018 Status changed from suspended to active, no longer recruiting.